S&P 500 Industrials Sector SEC Filings — May 26, 2026

26-05-2026

Destination XL Group, Inc. (DXLG) filed a Schedule 14D-9 recommending that stockholders reject the unsolicited tender offer from Zodiac Partners II, LLC (an acquisition entity of Camac Fund, LP) to purchase all outstanding shares at $0.82 per share in cash. The Board unanimously determined the offer is inadvisable and not in the best interests of stockholders, citing that the price represents a significant reduction from the Offeror's prior $1.25 per share proposal, the offer is highly conditional with no committed financing (only $10 million in equity from Camac Fund, less than 25% of the ~$46 million total consideration), and the Offeror has not obtained committed financing sufficient to consummate the offer. However, the Company itself had previously entered into a Merger Agreement with FBB Holdings I, Inc. on December 11, 2025, indicating an alternative transaction was already in place.

• · The Offer is scheduled to expire at 5:00 p.m., Eastern Time, on June 19, 2026, unless extended.
• · The Offer is subject to a financing condition; Offeror's only fully committed equity is $10 million from Camac Fund, representing less than 25% of the ~$46 million total consideration.
• · Offeror indicated in a May 21, 2026 press release that it might acquire control and not merge out stockholders who do not tender.
• · The Board had previously determined that Offeror's $1.25 per share proposal did not represent the best value and was not reasonably likely to lead to a DXL Superior Proposal.
• · The Company entered into a Merger Agreement with FBB Holdings I, Inc. on December 11, 2025, prior to the Offer.
• · Offeror submitted a books and records demand under Section 220 of the DGCL on May 13, 2026, which the Company responded to on May 20, 2026, stating the demand was deficient.
• · The Company's financial advisor is not named in the filing, but MacKenzie Partners is identified as the information agent for stockholders to withdraw shares.

26-05-2026

Bleichroeder Acquisition Corp. II (BBCQU) filed an 8-K with an investor presentation detailing its proposed business combination with Pasqal, a quantum computing company. Pasqal has 7 commercial QPUs installed and 3 in production, with €16.5M in 2025 commercial revenue and €66M+ in booked/awarded business. However, the company is pre-revenue at scale and faces significant competition from better-capitalized peers (e.g., IBM, Google, IonQ) with $550M+ raised versus competitors' $1.2B-$4B+.

• · Pasqal's technology uses neutral atoms, operating at room temperature with only 4 kW power consumption, no deep cryogenics required.
• · Pasqal demonstrated quantum advantage in materials simulation of TmMgGaO4, a real frustrated magnet, with results matching measurements from the MagLab.
• · The company's roadmap targets 10,000+ physical qubits and 200+ logical qubits with 99.9999% fidelity by 2029.
• · Pasqal has 85+ patents (53 hardware, 33 software) and is part of the IBM Quantum Network and Nvidia's NVQLink initiative.
• · Key customers include Aramco (Oil & Gas), Credit Agricole (Financial Services), LG Electronics (Specialty Materials), and CMA-CGM (Logistics).
• · The company has raised $550M+ total, but competitors have raised significantly more: IBM $4B+, Google $1.5B+, IonQ $1.2B+, Quantinuum $1.2B+, D-Wave $350M+.
• · Pasqal's QPU count (10) exceeds competitors: IonQ (6), Quantinuum (3), IBM (3), D-Wave (3).
• · The projected total addressable market for quantum computing is $720B by 2040, with Pasqal addressing all five segments (Advanced Materials & Energy $230B, Life Sciences & Pharma $200B, Logistics & Transport $190B, Financial Services $70B, Cross-Sector $30B).

26-05-2026

BANK5 2026-5YR22 filed an 8-K on May 26, 2026, announcing the entry into underwriting and certificate purchase agreements for a $832,639,742 commercial mortgage-backed securities (CMBS) transaction, with a closing date scheduled for June 11, 2026. The transaction involves 27 commercial and multifamily mortgage loans and includes both publicly offered certificates ($735,845,000) and privately offered certificates ($96,794,742). The filing details the formation of the issuing entity, the roles of multiple sponsors and underwriters, and the execution of various related agreements.

• · The Underwriting Agreement was entered into on May 21, 2026, with the closing date scheduled for on or about June 11, 2026.
• · The registration statement (file no. 333-282099) was originally declared effective on December 2, 2024.
• · The issuing entity is a common law trust formed under New York law.
• · Certain whole loans are not serviced under the main Pooling and Servicing Agreement but under separate Non-Serviced PSAs, with specific servicing arrangements for the 1500 Post Oak Boulevard whole loan via a Primary Servicing Agreement with Trimont.
• · The Mortgage Loans are acquired from four sponsors: Wells Fargo Bank, Bank of America, Morgan Stanley Mortgage Capital Holdings, and JPMorgan Chase Bank.

26-05-2026

Genco Shipping & Trading Ltd filed a DEFA14A on May 26, 2026, responding to Diana Shipping's unsolicited takeover bid and proxy contest. Genco argues Diana's $23.50 per share offer is inadequate, representing a discount to NAV and lacking a control premium, while highlighting its own strong performance and dividend payments. However, Genco acknowledges that its stock has closed above the offer price only 40% of trading days in 2026 and that dry bulk peers trade at a ~25% discount to NAV, indicating downside risk in a no-transaction scenario.

• · Genco's fleet grew by 20% in 2025 without issuing new shares.
• · Diana's market cap is $321M, 45% of its stated net asset value of $710M.
• · Diana's lagging time charter fixtures have cost Diana shareholders over $40M in 2026 alone.
• · Diana has raised more than $1bn in equity and issued $528m in unsecured and preferred notes, of which $288m has been repaid.
• · On February 25, 2026, Diana's board approved the award of 7.75m shares of restricted common stock to executive management and non-executive directors, fair value $20M.
• · Genco's stock has closed above Diana's offer price 40% of trading days in 2026 and more than 80% of the time since April 1, 2026.
• · Dry bulk peers on average trade at a ~25% discount to NAV, highlighting downside risk in a no-transaction scenario.
• · Public precedent shipping takeovers have on average priced at a 20% discount to NAV.

26-05-2026

TriCo Bancshares (TCBK) announced a quarterly cash dividend of $0.36 per share, payable on June 26, 2026 to shareholders of record as of June 5, 2026. The dividend was declared by the Board of Directors on May 21, 2026. No comparative prior dividend or performance metrics were provided in the filing.

• · Dividend record date: June 5, 2026
• · Dividend payable date: June 26, 2026
• · Filing date: May 26, 2026; event date: May 21, 2026

26-05-2026

Cumberland Pharmaceuticals Inc. (CPIX) entered into an Asset Purchase Agreement on April 22, 2026, to sell its FDA-approved product assets (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) to an affiliate of Apotex Inc. for $100M in cash. The pro-forma financials show the company would have retained a significantly smaller revenue base of $168,850 for the three months ended March 31, 2026, down from $9.1M historically, while also showing a pro-forma net loss of $1.73M for that period. However, the company would have received a substantial cash infusion, with pro-forma cash and cash equivalents of $110.2M as of March 31, 2026, up from $11.0M historically, and will retain its earlier-stage ifetroban product candidates and majority-owned subsidiary Emerging Technologies, Inc.

• · The transaction is expected to close with a transition services agreement where Cumberland will provide services to Apotex for up to 12 months post-closing.
• · Pro-forma basic and diluted net loss per share for the three months ended March 31, 2026 is $(0.12), compared to a historical loss of $(0.22).
• · Pro-forma basic and diluted net loss per share for FY2025 is $(0.53), compared to a historical loss of $(0.19).
• · Pro-forma basic and diluted net loss per share for FY2024 is $(0.45), compared to a historical loss of $(0.46).
• · The company will retain $5.2M in revolving line of credit debt on a pro-forma basis.
• · The pro-forma balance sheet eliminates $12.7M in intangible assets and $914,000 in goodwill related to the sold assets.

26-05-2026

AITX announced that its subsidiary RAD has added 12 more RIO Minis at a massive construction site, as per a press release issued on May 26, 2026. The filing is an 8-K furnishing the press release under Item 8.01, with no financial details or performance metrics provided.

• · The press release is titled 'AITX's RAD Adds 12 More RIO Minis at Massive Construction Site'.
• · The filing is dated May 26, 2026, and is furnished under Item 8.01.

26-05-2026

Octave Intelligence plc, a spin-off from Hexagon AB, announced the distribution of its shares to Hexagon shareholders and the commencement of trading on Nasdaq Stockholm (SDRs under 'OCTV SDB') and Nasdaq New York (class B ordinary shares under 'OCTV'), with the first day of regular-way trading on Nasdaq New York expected on May 28, 2026. The company also designated Ireland as its Home Member State for regulatory purposes. The filing highlights the successful separation from Hexagon and the dual listing, but notes forward-looking risks related to operating as an independent public company and market conditions.

• · Share distribution ratio: one class A ordinary share in Octave for every ten Series A shares held in Hexagon, and one class B ordinary share for every ten Series B shares held in Hexagon.
• · Record date for distribution: May 22, 2026.
• · SDRs trade on Nasdaq Stockholm under ticker 'OCTV SDB' with ISIN SE0028329433.
• · Class B ordinary shares trade on Nasdaq New York under ticker 'OCTV' with ISIN IE0003YHD8K8 and CUSIP G22845 104.
• · First day of regular-way trading on Nasdaq New York expected May 28, 2026.
• · SDR conversion to underlying class B ordinary shares is free of charge for the first six months from the first day of trading on Nasdaq Stockholm; thereafter a conversion fee applies.
• · Octave is an Irish company with registered office in Ireland and has chosen Ireland as its Home Member State.
• · Forward-looking statements caution about risks including separation from Hexagon, independent operations, market conditions, and competitive pricing.

26-05-2026

Global Interactive Technologies, Inc. (GITS) filed its 10-K annual report for the fiscal year ended May 26, 2026, detailing its monetization model centered on Vote & Boost sales, premium subscriptions, and scalable advertising. The company continues to incur recurring losses, has a working capital deficiency, and its auditors have expressed substantial doubt about its ability to continue as a going concern, requiring significant additional capital. Despite these risks, GITS is expanding its IP portfolio (including music distribution and The Nut Job 3) and leveraging a user-centric economy with 50% of daily net advertising profits distributed as FP to users.

• · The company's auditors have stated that substantial doubt exists about its ability to continue as a going concern.
• · The company has incurred recurring losses from operations and has a working capital deficiency.
• · The company requires significant additional capital to continue as a going concern.
• · The value of FP is maintained at a fixed ratio of 1 FP to 100 Korean Won.
• · The company expanded its IP portfolio in 2025 to include distribution of music for K-pop artists and international animation projects such as The Nut Job 3.
• · The real-time translation engine currently supports 17 languages.
• · Communications are protected through end-to-end encryption (E2EE).
• · New communities are automatically activated when user requests for a specific topic reach a strategic threshold.
• · The company plans to produce 2-minute short-form cultural content for distribution on Faning and third-party social media networks.

26-05-2026

TransCode Therapeutics disclosed it received a Nasdaq deficiency letter on May 19, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting only $1,251,427 in equity as of March 31, 2026. The company has until July 3, 2026, to submit a compliance plan, which hinges on stockholder approval to convert Series A and Series B Preferred Stock into common stock. Failure to regain compliance could lead to delisting, materially impacting the company's operations and share value.

• · The company's common stock trades on the Nasdaq Capital Market under the symbol RNAZ.
• · If stockholder approval for conversion of Series A Preferred Stock is not obtained by December 31, 2026, holders can elect redemption at estimated fair value.
• · As of March 31, 2026, Series A Preferred Stock was classified as temporary equity due to the redemption feature.
• · The company also plans to seek approval for conversion of Series B Non-Voting Convertible Preferred Stock and a 'change of control' under Nasdaq rules.
• · A preliminary proxy for the stockholder meeting was filed on May 8, 2026.

26-05-2026

Amerant Bancorp Inc. filed an 8-K on May 26, 2026, disclosing an investor presentation (Exhibit 99.1) to be used with existing and prospective investors. The filing is a Regulation FD disclosure and does not contain any financial results or material operational updates.

• · The presentation is attached as Exhibit 99.1 and incorporated by reference.
• · The information is furnished under Item 7.01 and not deemed filed for Section 18 liability purposes.
• · The filing includes a cover page interactive data file (Inline XBRL).

26-05-2026

Olema Pharmaceuticals entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor, OP-3136, in combination with Bayer's NUBEQA (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer (mCRPC). The study, expected to initiate in H2 2026, will enroll approximately 36 patients, with Bayer supplying darolutamide and Olema leading the study. The agreement is the first clinical collaboration for OP-3136, and Olema retains full global commercial and marketing rights to the compound.

• · The Phase 1b/2 study will evaluate safety, tolerability, and preliminary anti-tumor activity.
• · Bayer will supply darolutamide; Olema will lead the conduct of the study.
• · Clinical data and inventions related to the combined use will be jointly owned.
• · Olema maintains full global commercial and marketing rights to OP-3136.
• · This is the first clinical collaboration for OP-3136.

26-05-2026

Passage Bio, Inc. held its 2026 Annual Meeting on May 19, 2026, where stockholders elected two Class III directors (Athena Countouriotis, M.D. and Sandip Kapadia) for three-year terms, ratified KPMG LLP as independent auditor for fiscal 2026, and approved on a non-binding advisory basis the compensation of named executive officers and a frequency of every year for future advisory votes on such compensation. All proposals were adopted, with the auditor ratification receiving the strongest support (2,083,031 shares for, 41,539 against).

• · The annual meeting was held on May 19, 2026, and the 8-K was filed on May 26, 2026.
• · Broker non-votes totaled 637,397 shares for director elections and the advisory compensation votes.
• · The auditor ratification had no broker non-votes, indicating it was a routine matter.
• · The board adopted a policy to hold advisory votes on executive compensation every year until the next required frequency vote.

26-05-2026

Applied Aerospace & Defense, Inc. filed Amendment No. 1 to its S-1 registration statement for an initial public offering of 32,500,000 shares of common stock, with an estimated price range of $18.00 to $21.00 per share. The company will list on the NYSE under symbol 'AADX'. Post-IPO, affiliates of Greenbriar Equity Group will own approximately 81.0% of the common stock, making it a 'controlled company'. The company qualifies as an 'emerging growth company' and has elected reduced public company reporting requirements.

• · The company was originally formed as GB Eagle Topco, Inc. on October 7, 2022 and changed its name to Applied Aerospace & Defense, Inc. on November 14, 2025.
• · On November 14, 2025, AA&D Holdings, LP completed a merger with Rotor Topco, LP, combining the businesses of Applied Aerospace Structures Corporation and PCX Aerostructures, LLC.
• · The combination was accounted for as a common control transaction under common control of Greenbriar Equity Fund V, L.P.
• · The company has applied to list on the NYSE under the symbol 'AADX'.
• · The underwriters have a 30-day option to purchase up to an additional 4,875,000 shares.
• · Up to 1,625,000 shares (5.0% of the offering) are reserved for a directed share program for directors, officers, employees, and others.
• · The company is an 'emerging growth company' and has elected to use reduced public company reporting requirements.
• · Post-IPO, the company will be a 'controlled company' under NYSE rules due to Greenbriar's ownership.

26-05-2026

Ameris Bancorp held its Annual Meeting on May 21, 2026, with 88.38% of outstanding shares represented. Shareholders elected 10 directors, ratified KPMG LLP as auditor for 2026, and approved executive compensation on an advisory basis. All proposals passed, though director William H. Stern received the lowest support with 50,067,725 votes for and 6,575,312 against.

• · William H. Stern received the lowest support among director nominees with 50,067,725 votes for and 6,575,312 against.
• · Ratification of KPMG LLP as auditor passed overwhelmingly with 60,277,906 votes for, 45,689 against, and 18,339 abstentions.
• · Advisory vote on executive compensation passed with 55,662,993 for, 898,391 against, and 121,588 abstentions.
• · Broker non-votes totaled 3,658,962 for all director elections and the executive compensation proposal.
• · The meeting was held on May 21, 2026, and the filing was made on May 26, 2026.

26-05-2026

General Motors filed a DEFA14A supplement to its definitive proxy statement on May 26, 2026, announcing that director nominee Jonathan McNeill will not stand for reelection at the June 2, 2026 annual meeting and will retire from the board. As a result, the board size will be reduced from 11 to 10 directors, with no replacement nominee. Proxies already submitted remain valid, but votes for McNeill will be disregarded.

• · The supplement updates the proxy statement dated April 20, 2026, for the annual meeting scheduled for June 2, 2026.
• · McNeill notified the board of his decision on May 26, 2026.
• · Proxies already returned remain valid and will be voted as directed, except votes for McNeill will be disregarded.
• · Stockholders who have already voted do not need to take any action unless they wish to change their vote.

26-05-2026

This DEFA14A filing is an additional proxy soliciting material submitted by Ardelyx, Inc. on May 26, 2026, which incorporates by reference forward-looking statements from an earlier filing on April 30, 2026. The document is a brief 4-page communication with no new financial figures or substantive business updates, serving primarily as a legal notice regarding forward-looking statements and the company's disclaimers.

• · Filing references forward-looking statements originally filed with the SEC on April 30, 2026
• · The document is 4 pages in length and contains no new operational or financial metrics
• · Ardelyx explicitly states it undertakes no obligation to update forward-looking statements except as required by law

26-05-2026

On May 21, 2026, NorthEast Community Bancorp, Inc. held its annual meeting where stockholders elected four directors for three-year terms and approved the 2026 Equity Incentive Plan. The appointment of S.R. Snodgrass, P.C. as independent auditor for fiscal year 2026 was also ratified. Director John F. McKenzie received a relatively high number of withheld votes (2,003,337), representing about 22.6% of votes cast, indicating notable shareholder dissent.

• · The annual meeting was held on May 21, 2026.
• · All four director nominees were elected for three-year terms.
• · The 2026 Equity Incentive Plan was approved with 8,177,774 votes FOR, 553,081 AGAINST, and 139,307 abstentions.
• · Ratification of S.R. Snodgrass, P.C. as independent auditor passed with 10,833,710 FOR, 138,801 AGAINST, and 225,861 abstentions.
• · There were 2,328,210 broker non-votes on the director election and equity plan proposals, but none on the auditor ratification.

26-05-2026

On May 21, 2026, Neuphoria Therapeutics received a revenue distribution payment of AUD $1.416M from the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to its licensing of the KAT6 program to Pfizer, triggered by the initiation of the first Phase III clinical trial in ER+/HER2- metastatic breast cancer. Neuphoria is eligible for ~4.65% of future milestone payments from a total estimated pool of USD $460M across 17 parties, but as a passive party, the company cannot guarantee it will receive any future milestones or their size. Total distributions received to date from the CRC trusts amount to AUD $3.52M since 2016.

• · Revenue distribution payment of AUD $1,416,026 was received on May 21, 2026 from CTx CRC related to licensing of the KAT6 program to Pfizer.
• · The payment was triggered by initiation of dosing of the first subject in the first Phase III Clinical Trial in ER+/HER2- metastatic breast cancer.
• · Neuphoria believes it is eligible to receive approximately 4.65% of future milestone payments from CTXT, with the total value across all 17 parties estimated at USD $460M.
• · The company has received total CRC trust distributions of AUD $3,522,413.68 since 2016.
• · Historical annual revenues from CTx CRC include: AUD $967,583 (2016), AUD $654,149 (2018), AUD $46,662 (2020), AUD $263,634 (2021), AUD $22,047 (2022), AUD $8,295 (2023), AUD $23,717 (2024), AUD $120,298 (2026).
• · The CTx CRC concluded in December 2020 and evolved into Canthera Discovery.

26-05-2026

Cogent Communications Holdings, Inc. announced a definitive agreement to sell 10 data center facilities to a newly formed entity sponsored by I Squared Capital for $225 million in cash. The transaction is expected to close on or after June 12, 2026, subject to HSR Act waiting period expiration. The sale represents a strategic divestiture of non-core assets, but no financial impact or gain/loss details were disclosed.

• · The 10 facilities are located in Phoenix, AZ; Anaheim, CA; Burbank, CA; Stockton, CA; Atlanta, GA; Chicago, IL; Elkridge, MD; Kansas City, MO; Nashville, TN; and Houston, TX.
• · The transaction is expected to close on the later of June 12, 2026 and the expiration or termination of the HSR Act waiting period.
• · Cogent's all-optical IP network provides services in 306 markets globally.
• · No financial details on expected gain, loss, or use of proceeds were provided.

26-05-2026

Global Net Lease, Inc. held its 2026 annual meeting on May 21, 2026, where all eight director nominees were elected, PricewaterhouseCoopers LLP was ratified as auditor, and executive compensation was approved on a non-binding advisory basis. Additionally, following the retirement of two directors, the Board appointed Lisa Kabnick to the Audit Committee and Dr. M. Therese Antone to the Nominating and Corporate Governance Committee.

• · Proposal 1: All eight director nominees received a majority of votes for, with the highest votes for Lisa D. Kabnick (151,518,868 for) and the lowest for Leslie D. Michelson (135,211,852 for).
• · Proposal 2: Ratification of PwC as auditor passed with 179,564,468 votes for, 1,151,933 against, and 436,602 abstentions.
• · Proposal 3: Non-binding advisory vote on executive compensation passed with 145,876,071 for, 6,366,683 against, and 590,309 abstentions.
• · Broker non-votes on Proposals 1 and 3 were 28,319,940; there were no broker non-votes on Proposal 2.
• · Board committee composition updated: Audit Committee (Stanley R. Perla Chair, Lisa D. Kabnick, Leon C. Richardson); Compensation Committee (Dr. M. Therese Antone Chair, Michael J.U. Monahan, Stanley R. Perla); Finance Committee (Robert I. Kauffman Chair, Lisa D. Kabnick, Michael J.U. Monahan, Edward M. Weil, Jr.); Nominating and Corporate Governance Committee (Leslie D. Michelson Chair, Dr. M. Therese Antone, Leon C. Richardson).

26-05-2026

Urban Outfitters, Inc. entered into a Fifth Amendment to its Credit Agreement on May 19, 2026, extending the Maturity Date, terminating the Canadian sub-facility, and releasing URBN Canada Retail, Inc. from its obligations and liens. The amendment requires the company to maintain at least $225 million in aggregate availability after giving effect to the amendment. No financial performance metrics or period-over-period comparisons are provided in this filing.

• · The amendment was dated May 19, 2026, and filed on May 26, 2026.
• · The original credit agreement was dated June 29, 2018, and had been amended four times previously.
• · The amendment includes the release of URBN Canada from all obligations and liens under the credit agreement.
• · Departing Canadian Lenders were paid in full for principal, accrued interest, and fees as of the effective date.
• · Conditions for effectiveness included delivery of legal opinions, secretary's certificates, good standing certificates, and lien search results.

26-05-2026

NIQ Global Intelligence plc held its 2026 Annual General Meeting on May 21, 2026, where all four Class I director nominees were elected and all seven proposals were approved by shareholders. Key approvals included ratification of Ernst & Young LLP as independent auditor, advisory approval of executive compensation, authorization for market purchases of ordinary shares, and creation of distributable reserves. All director nominees received strong support with over 247 million votes for each, while the advisory vote on executive compensation frequency favored a one-year interval.

• · Proposal 5 (market purchases of ordinary shares) received 265,812,207 votes for, 173,814 against, and 30,472 abstentions, with no broker non-votes.
• · Proposal 6 (price range for re-allotment of treasury shares) received 265,720,147 for, 219,500 against, and 76,846 abstentions.
• · Proposal 7 (capital reduction and creation of distributable reserves) received 265,704,195 for, 180,946 against, and 131,352 abstentions.
• · The advisory vote on executive compensation frequency showed 254,069,090 votes for 1 year, 482 for 2 years, and 2,542,606 for 3 years.
• · All director nominees received over 244 million votes for, with Todd Lachman receiving the lowest for votes at 244,078,915.

26-05-2026

DuPont held its Annual Meeting on May 21, 2026, with 83.27% of shares voted. All 10 director nominees were elected, and shareholders approved executive compensation (Say-on-Pay) and ratified PwC as auditor. The Board approved a 1-for-3 reverse stock split, effective June 24, 2026, though it retains discretion to delay or abandon the split.

• · Shareholder support for executive compensation (Say-on-Pay) was 92.2% for vs. 7.3% against, with 0.5% abstain.
• · Ratification of PwC as auditor received 99.3% for votes (338.8M for, 2.0M against).
• · Reverse stock split amendment was approved with 98.3% for votes (335.5M for, 4.4M against).
• · Broker non-votes were 52.6M shares on director elections and executive compensation, but zero on the reverse split and auditor ratification.
• · The reverse stock split is expected to become effective on June 24, 2026, but the Board retains discretion to delay or abandon it.

26-05-2026

BlackRock Monticello Debt Real Estate Investment Trust entered into a First Amendment to its Revolving Credit Agreement with JPMorgan Chase Bank, N.A. on May 21, 2026. The amendment extends the stated maturity date to May 20, 2027 (from the original May 22, 2025 date) and adjusts the applicable interest rate margins to 0.85% for ABR loans and 1.85% for Term Benchmark or Daily Simple SOFR loans. The amendment also includes a facility extension fee of [***] basis points per annum on the maximum commitment, prorated through the new maturity date.

• · The amendment was executed on May 21, 2026 and filed on May 26, 2026.
• · The original credit agreement was dated May 22, 2025.
• · The amendment includes a facility extension fee of [***] basis points per annum on the maximum commitment, prorated from the prior maturity date to the new stated maturity date.
• · The borrower represented that no event of default, potential default, or mandatory prepayment event exists as of the amendment date.
• · The extended maturity date is no later than 30 days prior to the termination of the borrower's ability to call capital commitments for repaying obligations.

26-05-2026

Stoneridge, Inc. held its 2026 Annual Meeting on May 19, 2026, where shareholders approved all four proposals, including the election of nine director nominees, ratification of Ernst & Young LLP as auditor, approval of named executive officer compensation, and an amendment to the 2025 Long-Term Incentive Plan increasing authorized shares by 2,650,000. However, the non-binding advisory vote on executive compensation received significant opposition, with 25.5% of votes cast against it, indicating notable shareholder dissent.

• · The ratification of Ernst & Young LLP as independent auditor was overwhelmingly approved with 23,883,582 votes for, 194,854 against, and 88 abstentions.
• · Broker non-votes totaled 2,620,208 on all director elections and the advisory compensation vote, indicating a significant number of shares were not voted on those items.
• · The amendment to the 2025 Long-Term Incentive Plan received 17,773,424 votes for, 3,557,150 against, and 127,742 abstentions, representing about 16.7% opposition among votes cast.
• · The advisory vote on executive compensation had 15,986,309 votes for, 5,458,156 against, and 13,851 abstentions, with 25.5% of votes cast opposing the compensation.
• · All nine director nominees were elected with varying levels of support; Ira C. Kaplan received the highest number of withheld votes at 2,970,367, while Natalia Noblet received the fewest withheld votes at 175,722.

26-05-2026

Ardent Health, Inc. held its Annual Meeting of Stockholders on May 20, 2026, with 98,778,826 shares represented (69.0% of outstanding shares). All 11 director nominees were elected, and stockholders approved executive compensation on a non-binding advisory basis and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026. Notably, two director nominees—Rahul Sen and Ellen Havdala—received significant withhold votes (12,243,316 and 5,305,058, respectively), indicating notable shareholder dissent.

• · Rahul Sen received 79,335,440 votes for and 12,243,316 withhold (13.4% of votes cast against), the highest dissent among nominees.
• · Ellen Havdala received 86,273,698 votes for and 5,305,058 withhold (5.8% of votes cast against).
• · Peter Bynoe received 87,141,918 votes for and 4,436,838 withhold (4.8% of votes cast against).
• · The advisory vote on executive compensation passed with 91,093,535 for, 300,746 against, and 184,475 abstentions.
• · Ratification of Ernst & Young LLP as auditor passed overwhelmingly with 97,852,830 for, 918,233 against, and 7,763 abstentions.
• · Broker non-votes totaled 7,200,070 on all director elections and the advisory compensation vote.

26-05-2026

Howmet Aerospace Inc. held its 2026 annual meeting on May 19, 2026, with 364,912,140 shares represented (91.1% of 400,713,557 outstanding shares). All nine director nominees were elected, and both the ratification of PricewaterhouseCoopers LLP as auditor and the advisory vote on executive compensation were approved. However, the advisory vote on executive compensation received a notable 28.9% against votes (99,027,657 shares), indicating significant shareholder dissent.

• · Record date for the meeting was March 24, 2026.
• · Broker non-votes totaled 22,308,137 shares on all director elections and the executive compensation proposal.
• · The ratification of PricewaterhouseCoopers LLP as auditor received 342,356,156 for, 22,372,401 against, and 183,583 abstain (no broker non-votes).
• · Director nominee Joseph S. Cantie received the highest for votes (341,328,735) and the lowest against votes (1,116,810).
• · Director nominee James F. Albaugh received the most against votes (16,610,826) among director nominees.

26-05-2026

FG Merger II Corp., a SPAC, filed a Rule 425 communication regarding its proposed business combination with Boxabl Inc., a modular housing company known for its fast-deploying Casita unit and other foldable building systems. The filing discloses that on May 25, 2026, social media posts were made on X and Reddit related to the merger, and that a definitive proxy statement/prospectus was mailed to shareholders as of the record date, with the S-4 declared effective. The forward-looking statements caution that Boxabl has a limited operating history and has incurred net losses, faces significant technical and commercialization risks, and that there is no guarantee the merger's anticipated benefits will be realized.

• · Boxabl was founded in 2017.
• · The Casita unfolds on-site in less than one hour and includes a full kitchen, bathroom, and utilities.
• · The Baby Box is built to RV code and intended for simpler, no-foundation setups.
• · The Merger Agreement was entered into on August 4, 2025, and provides for a two-step merger structure.
• · The joint proxy statement/prospectus is dated May 12, 2026.
• · Boxabl's Annual Report on Form 10-K was filed with the SEC on March 27, 2026.
• · The filing explicitly disclaims any offer of securities and states no regulatory authority has endorsed the offering.

26-05-2026

Northwest Bancshares, Inc. held its Annual Meeting on May 20, 2026, where shareholders approved the 2026 Equity Incentive Plan and Discounted Stock Purchase Plan, elected directors, ratified KPMG as auditor, and approved executive compensation on an advisory basis. All proposals passed with strong support, though director Amber L. Williams received a notable 5.99 million withheld votes (6.2% of votes cast).

• · All director nominees were elected with over 91 million votes for each, but Amber L. Williams had the highest withheld votes at 5,989,717 (6.2% of votes cast).
• · Ratification of KPMG as auditor passed with 114,141,735 for, 1,967,195 against, and 247,020 abstentions.
• · Say-on-pay advisory vote passed with 89,274,329 for, 7,171,131 against, and 583,625 abstentions.
• · The 2026 Equity Incentive Plan was approved with 92,456,593 for, 4,152,782 against, and 419,710 abstentions.
• · The Discounted Stock Purchase Plan was approved with 93,563,437 for, 3,061,203 against, and 404,445 abstentions.
• · Broker non-votes were 19,326,865 for director elections, say-on-pay, and the two equity plans.

26-05-2026

ServisFirst Bancshares, Inc. filed an 8-K on May 26, 2026, disclosing an updated investor presentation containing current quarter financial information and other data. The presentation is attached as Exhibit 99.1 and will be used in discussions with investors. No specific financial figures or performance metrics were provided in the filing itself.

• · The updated investor presentation is available through the Investor Relations link at www.servisfirstbank.com.
• · The information in this 8-K is furnished, not filed, under Regulation FD and will not be incorporated by reference into any registration statement unless specifically identified.

26-05-2026

BlackRock ESG Capital Allocation Term Trust (ECAT) filed a DEFA14A (definitive additional proxy materials) with the SEC on May 26, 2026. The filing supplements the trust's proxy statement and includes soliciting material under Section 14(a) of the Securities Exchange Act of 1934. No fee was required for this filing.

• · Filing type: DEFA14A (Definitive Additional Proxy Materials)
• · SEC file number: 811-23701
• · Trust incorporated in Maryland (MD)
• · Business address: 100 Bellevue Parkway, Wilmington, DE 19809
• · Former name: BlackRock ESG Capital Allocation Trust (name changed May 27, 2021)

26-05-2026

Axiom Intelligence Acquisition Corp 1 (SPAC) announced a definitive Business Combination Agreement with Terra Quantum AG, a Swiss quantum technology company, dated May 25, 2026. The transaction will result in a new Swiss public company (PubCo) becoming publicly traded, with both Axiom and Terra Quantum becoming wholly owned subsidiaries of PubCo. No financial terms, valuations, or performance metrics were disclosed in this filing.

• · The Business Combination Agreement was signed on May 25, 2026, and the press release was issued on May 26, 2026.
• · The transaction structure involves a Swiss public company (PubCo) as the ultimate parent, with a Cayman Islands merger subsidiary.
• · Axiom's securities trade on Nasdaq under symbols AXINU (Units), AXIN (Class A ordinary shares), and AXINR (Rights).
• · Axiom is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.
• · A registration statement on Form F-4 will be filed with the SEC, containing a proxy statement/prospectus for shareholder vote.
• · No financial projections, deal value, or expected closing timeline were provided in this filing.

26-05-2026

Barnwell Industries reported Q2 FY2026 (ended March 31, 2026) revenue of $2.535M and a net loss of $1.15M, improving sequentially from Q1 FY2026 revenue of $2.63M and net loss of $1.426M. The company reduced costs, completed its headquarters transition to Houston, and advanced a strategic review including a potential sale of its Canadian oil and gas business. However, revenue declined year-over-year from $3.569M in Q2 FY2025, and the company continues to report net losses.

• · The company remained debt-free as of March 31, 2026.
• · Salaries, wages and bonuses declined 26% sequentially.
• · Oil and natural gas operating results improved to positive $87,000 from negative $32,000 in the prior quarter.
• · Foreign currency loss of $58,000 in Q2 vs gain of $47,000 in prior quarter, an unfavorable swing of $105,000.
• · The company has issued 1,810,496 shares under the ATM facility at an average price of $1.27/share.
• · The ATM facility limit was increased from $3.2M to $4.298M in April 2026.
• · The company holds a 77.6% economic interest in Kaupulehu Developments and a 19.6% interest in the KD entities.
• · Net loss per share improved to $0.09 from $0.13 sequentially, but was $0.09 vs $0.12 in the year-ago quarter.
• · Revenue for the six months ended March 31, 2026 was $5.281M, down 29.6% from $7.503M in the prior year period.
• · The company's weighted-average shares outstanding increased to 12.67M from 10.05M year-over-year due to equity issuances.

26-05-2026

OPGEN INC reported total revenue of $30.2M for 2025, a 481% increase from $5.2M in 2024, driven by a 504% surge in listing sponsorship services to $30.2M. However, product sales and laboratory services revenue dropped to zero as the company scaled down legacy operations. Operating expenses increased 27% to $6.2M, while net cash used in operations improved to $1.2M from $4.9M. The company repositioned its business, resulting in a net decrease in cash of $0.7M.

• · Cost of services increased from $1,575 to $3,020,000 (191,646% increase) due to new listing sponsorship business.
• · Gain on extinguishment of debt in 2024 was $9,738,487; no such gain in 2025.
• · Gain on impairment adjustment in 2024 was $2,079,575; none in 2025.
• · Net cash provided by financing activities was $496,719 in 2025 vs $5,028,574 in 2024.
• · Weighted average exercise price of outstanding options is $9.01.
• · No securities remaining available for future issuance under equity compensation plans.

26-05-2026

26-05-2026

Forgent Power Solutions, Inc. filed an S-1 registration statement on May 26, 2026, for its initial public offering. The filing details the company's structure, including its OpCo LLC and various parent entities, and outlines significant related-party transactions, sponsor fees, and debt facilities. The company has a history of net losses and negative retained earnings, indicating ongoing financial challenges.

• · The filing includes multiple debt facilities: 2023 Term Loan Facility, 2025 Term Loan Facility, and a Senior Secured Revolving Line of Credit.
• · Related-party transactions include sponsor fees and expenses, revenue from related parties, and operating leases.
• · The company has a history of net losses and negative retained earnings, with retained earnings of $0 as of March 31, 2026.
• · The IPO involves Class A common stock, with a follow-on offering also mentioned.
• · The filing date is May 26, 2026, and the balance sheet date is March 31, 2026.

26-05-2026

Kiniksa Pharmaceuticals International, plc filed an 8-K on May 26, 2026, reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement was entered into, but no specific financial terms, counterparty, or strategic details are disclosed in the summary. The filing is timely and mandatory, but the lack of quantitative data limits assessment of materiality.

• · Filing date: May 26, 2026
• · Filing size: 241 KB
• · AccNo: 0001730430-26-000025
• · Sector: not specified

26-05-2026

Angel Oak Financial Strategies Income Term Trust (FINS) completed a $50M private placement of Series A Mandatorily Redeemable Preferred Shares (rated A3/Moody's) and a $40M private offering of Series C Senior Notes (rated A1/Moody's). The proceeds will refinance existing debt and support new investments. The Fund also set a record date of July 10, 2026 and an annual shareholder meeting for September 25, 2026, with proposals including trustee elections, a governance amendment to lower the trustee removal threshold, and ratification of the auditor.

• · MRPS due April 30, 2031; Series C Notes due July 8, 2030, Series B Notes due July 8, 2028.
• · Series C Notes are rated A1; MRPS rated A3 by Moody's.
• · Series C Notes will replace maturing Series A Senior Notes (2.35%, due July 8, 2026) in July 2026 via delayed draw.
• · Repurchase agreement leverage $75.5M (unrated in table).
• · Shareholders vote on six proposals: elect two Class II trustees, MRPS holders elect one Class III trustee, lower removal threshold from 75% to 66.67%, approve adjournments, ratify Cohen & Company as auditor, and other business.
• · Notice deadline for shareholder nominations/business: between 150th and 120th day prior to meeting, or 10 days after public announcement if later.

26-05-2026

Traws Pharma, Inc. filed an 8-K on May 26, 2026, updating its At The Market Offering Agreement with Citizens JMP Securities, LLC. Under a new prospectus supplement dated May 22, 2026, the company may now offer and sell up to $3,128,399 in common shares, which is its current ‘baby shelf’ limitation under Form S-3. This update follows the original $50,000,000 shelf registration established in March 2025, but no new financial performance data or operational changes were disclosed.

• · The opinion of Snell & Wilmer L.L.P. regarding the legality of the shares is filed as Exhibit 5.1 to the 8-K.
• · The original ATM Agreement was entered into on March 10, 2025, and the shelf registration (No. 333-273081) was declared effective on July 11, 2023.
• · The proceeds from future sales will be used for general corporate purposes, though no specific use is detailed in this filing.

26-05-2026

Global Tech Industries Group, Inc. (GTII) filed an 8-K on May 26, 2026, reporting that the court-appointed Receiver filed a Seventh Interim Report on April 29, 2026, covering activities through April 21, 2026. The report details the resignation of the Company's independent auditor, the status of audits for fiscal years 2023 and 2024, continued accounting of misappropriated funds, and related real-property and litigation matters. The filing highlights ongoing financial and operational challenges under receivership, with no positive financial metrics reported.

• · The Receiver was appointed on September 18, 2024, by the Eighth Judicial District Court of Nevada in Case No. A-24-896359-B.
• · The Seventh Interim Report covers the period from the Sixth Interim Report through April 21, 2026.
• · The report addresses the resignation of the Company's independent registered public accounting firm.
• · The audit status for fiscal years ended December 31, 2023 and December 31, 2024 is discussed.
• · The report includes continued accounting of misappropriated Company funds, real-property and storage matters, and pending litigation.

26-05-2026

Evolution Metals & Technologies Corp. (EMAT) received a Nasdaq deficiency notice on May 21, 2026 for failing to timely file its Q1 2026 Form 10-Q (Rule 5250(c)(1)). The company filed the delinquent report on May 22, 2026, and Nasdaq confirmed compliance on May 26, 2026, closing the matter. No financial impact or ongoing listing risk was associated with the event, though the late filing suggests potential internal administrative delays.

• · The company filed a Form 12b-25 on May 15, 2026, disclosing it could not file the Form 10-Q on time without unreasonable effort or expense.
• · EMAT's common stock trades under the symbol EMAT on The Nasdaq Stock Market LLC.
• · The company changed its name from Welsbach Technology Metals Acquisition Corp. (effective June 7, 2021).
• · The notice had no immediate effect on the listing of the company's common stock.
• · Principal executive offices are located at 4040 NE 2nd Ave, Suite 349, Miami, Florida 33137.